Post by Tony Crispino on Apr 9, 2014 12:04:27 GMT -8
Upcoming Webinar on April 22 from the NCCN. Membership is required but patients can apply.
A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
Summary:
New evidence from multiple clinical trials may impact management of prostate cancer across the disease spectrum. For low-risk local tumors, Wilt et al reported similar survival in men randomized to surgery or observation, adding to the ongoing debate on the management of early tumors detected by PSA testing. With a median follow-up of 10 years, a phase III intergroup trial confirmed a significant survival advantage of adding radiation to androgen deprivation therapy in patients with locally advanced prostate cancer.
For metastatic disease, a phase III randomized intergroup study found that the popular approach of intermittent hormone therapy shortens survival compared to continuous therapy. In addition to its approved use in the post-docetaxel setting, abiraterone acetate is also associated with favorable survival in chemotherapy-naïve patients in a new phase III study. Other therapies that have been approved based on randomized phase III data include sipuleucel-T, cabazitaxel, and denosumab. New agents continue to produce encouraging results in the treatment of castration-recurrent prostate cancer. Both the anti-androgen enzalutamide and radioactive agent alpharadin demonstrated improved survival in randomized clinical trials.
A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
Summary:
New evidence from multiple clinical trials may impact management of prostate cancer across the disease spectrum. For low-risk local tumors, Wilt et al reported similar survival in men randomized to surgery or observation, adding to the ongoing debate on the management of early tumors detected by PSA testing. With a median follow-up of 10 years, a phase III intergroup trial confirmed a significant survival advantage of adding radiation to androgen deprivation therapy in patients with locally advanced prostate cancer.
For metastatic disease, a phase III randomized intergroup study found that the popular approach of intermittent hormone therapy shortens survival compared to continuous therapy. In addition to its approved use in the post-docetaxel setting, abiraterone acetate is also associated with favorable survival in chemotherapy-naïve patients in a new phase III study. Other therapies that have been approved based on randomized phase III data include sipuleucel-T, cabazitaxel, and denosumab. New agents continue to produce encouraging results in the treatment of castration-recurrent prostate cancer. Both the anti-androgen enzalutamide and radioactive agent alpharadin demonstrated improved survival in randomized clinical trials.